Allogeneic peripheral blood stem cell transplantation(PBSCT) for 27 patients with leukemia

    BAI Qingª²Xian,CHEN Xieª²Qun,WANG Wenª²Qing, DONG Baoª²Xia,LI Rui,SHI Mei,LI Lin

    1Department of Hematology£¬ 2Department of Radiotherapy,3 Department of Transfusion, Xijing Hospital£¬Fourth Military Medical University£¬ Xi¬ðan 710033£¬ China

    ¡¾Abstract¡¿AIM£º To observe the efficacy and main complications of allogeneic peripheral blood stem cell transplantation(alloª²PBSCT) in 27 patients with leukemia. METHODS: Twentyª²seven leukemia patients including 10 acute myeloid leukemia (AML), 8 acute lymphocytic leukemia (ALL) and 9 chronic myelogenous leukemia (CML) received allo-PBSCT from HLAª²identical sibling (n = 25)and 1~2 locus mismatched sibling(n = 2). Conditioning regimen consisted of cyclophosphamide and total body irradiation plus Araª²c/VPª²16(n=13) or busulphanª²cyclophosphamide(n = 14). Graft versus-host disease (GVHD) prophylaxis was the standard methotrexate and cyclosporine combination. ATG and CD25 monoclonal antibody was given in one case of 2-locus mismatched alloª²PBSCT. RESULTS: Twenty-seven patients got sustained engraftment. ¢òª²¢ó degree acute GVHD and chronic GVHD were found in 3/27(11%) and 7/27(26%) patients, respectively. Idiopathic pneumonia syndrome occurred in 1 case. Pure red cell aplasia lasted for 8 months in one patient with major ABO and Rh incompatible PBSCT. With a followª²up of 2 to 30 months, 20/27(74%) patients were still alive and 7/27 (26%) died of leukemia relapse. CONCLUSION: Allogeneic peripheral heamatopoietic stem cell transplantation is an effective therapy for leukemia, but there is high rate of relapse in patients with highª²risk and refractory status before transplantation. ......